VM4.F Vanda Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
3.50 EUR
Close of Nov 13, 2026
3.17 8.95
Market cap
EUR 212M
P/E
-
P/B
1.21x
ROE
-89.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is VM4.F undervalued?

Graham number

The Graham number of Vanda Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vanda Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Vanda Pharmaceuticals Inc yet.

Vanda Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; …

Full company profile